FAAS
TEVA icon

First Allied Advisory Services’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

First Allied Advisory Services’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$326K Buy
36,179
+12,467
+53% +$132K 0.01% 869
2020
Q2 		$292K Sell
23,712
-1,786
-7% -$20.2K 0.01% 848
2020
Q1 		$229K Buy
25,498
+205
+0.8% +$2.1K 0.01% 878
2019
Q4 		$251K Sell
25,293
-354
-1% -$3.16K 0.01% 1014
2019
Q3 		$166K Sell
25,647
-17,365
-40% -$133K 0.01% 1143
2019
Q2 		$397K Buy
43,012
+4,262
+11% +$51.4K 0.01% 770
2019
Q1 		$617K Sell
38,750
-653
-2% -$11.5K 0.02% 607
2018
Q4 		$618K Sell
39,403
-2,269
-5% -$46.5K 0.02% 546
2018
Q3 		$906K Buy
41,672
+6,733
+19% +$156K 0.03% 497
2018
Q2 		$840K Sell
34,939
-2,176
-6% -$44.4K 0.03% 505
2018
Q1 		$645K Buy
37,115
+321
+0.9% +$6.27K 0.02% 575
2017
Q4 		$689K Sell
36,794
-2,526
-6% -$38K 0.03% 547
2017
Q3 		$697K Buy
39,320
+3,413
+10% +$76.8K 0.03% 513
2017
Q2 		$1.18M Sell
35,907
-258
-0.7% -$7.99K 0.05% 372
2017
Q1 		$1.15M Sell
36,165
-497
-1% -$17K 0.06% 330
2016
Q4 		$1.33M Buy
36,662
+3,226
+10% +$129K 0.07% 310
2016
Q3 		$1.54M Buy
33,436
+507
+2% +$26.5K 0.08% 260
2016
Q2 		$1.66M Buy
32,929
+701
+2% +$37.3K 0.09% 246
2016
Q1 		$1.71M Buy
32,228
+1,513
+5% +$88.8K 0.1% 232
2015
Q4 		$2.01M Buy
30,715
+2,596
+9% +$160K 0.1% 222
2015
Q3 		$1.59M Buy
28,119
+1,382
+5% +$89.6K 0.09% 263
2015
Q2 		$1.58M Buy
26,737
+802
+3% +$49.5K 0.07% 305
2015
Q1 		$1.61M Buy
25,935
+7,565
+41% +$440K 0.11% 227
2014
Q4 		$1.06M Buy
18,370
+1,563
+9% +$87.1K 0.08% 306
2014
Q3 		$902K Buy
16,807
+1,309
+8% +$69.3K 0.07% 318
2014
Q2 		$800K Sell
15,498
-5,926
-28% -$303K 0.06% 387
2014
Q1 		$1.12M Sell
21,424
-3,471
-14% -$160K 0.08% 269
2013
Q4 		$1M Sell
24,895
-149,621
-86% -$5.89M 0.08% 290
2013
Q3 		$6.62M Buy
174,516
+31,809
+22% +$1.24M 0.39% 65
2013
Q2 		$5.65M Buy
+142,707
New +$5.56M 0.45% 41

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

First Allied Advisory Services's TEVA Position: Q3 2020 in Review

First Allied Advisory Services increased its Teva Pharmaceutical Industries Limited (TEVA) stake by 53% in Q3 2020, buying an estimated $132K and bringing the position to 36,179 shares worth $326K. The position accounts for 0.01% of the portfolio, ranked #869.

First Allied Advisory Services first reported a position in TEVA in Q2 2013 and has held it in 30 quarters since. The position peaked at $6.62M in Q3 2013. 444 funds tracked by Wall St. Rank hold TEVA as of Q3 2020.

  • First Allied Advisory Services held 36,179 shares of Teva Pharmaceutical Industries Limited worth $326K as of Q3 2020.
  • First Allied Advisory Services bought 12,467 Teva Pharmaceutical Industries Limited shares in Q3 2020, an estimated $132K.
  • Teva Pharmaceutical Industries Limited made up 0.01% of First Allied Advisory Services's portfolio in Q3 2020, its #869 holding.
  • First Allied Advisory Services first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and has held it in 30 quarters since.
  • First Allied Advisory Services's Teva Pharmaceutical Industries Limited position peaked at $6.62M in Q3 2013.
  • 444 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.